07/08/2022
𝐋𝐮-𝟏𝟕𝟕 𝐏𝐒𝐌𝐀 𝐭𝐡𝐞𝐫𝐚𝐩𝐲- 𝐋𝐚𝐭𝐞𝐬𝐭 𝐅𝐃𝐀 𝐚𝐩𝐩𝐫𝐨𝐯𝐞𝐝 𝐭𝐡𝐞𝐫𝐚𝐩𝐲 𝐟𝐨𝐫 𝐦𝐞𝐭𝐚𝐬𝐭𝐚𝐭𝐢𝐜 𝐜𝐚𝐬𝐭𝐫𝐚𝐭𝐢𝐨𝐧-𝐫𝐞𝐬𝐢𝐬𝐭𝐚𝐧𝐭 𝐩𝐫𝐨𝐬𝐭𝐚𝐭𝐞 𝐜𝐚𝐧𝐜𝐞𝐫 (𝐦𝐂𝐑𝐏𝐂)
Lu-177 PSMA therapy is a new latest advancement in the treatment of metastatic castration-resistant prostate cancer that has been recently approved by the FDA.
The first PSMA-targeted, Lu-177 PSMA therapy was successfully realized in April 2013 in Bad Berka-Germany and since then it has done wonders in controlling the progression of the mCRPC.
You can read more information about the therapy via the link below and can also apply to get a free quote from the hospital through Booking Med Travel.
https://bit.ly/3yQqNq4
